Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P06737
UPID:
PYGL_HUMAN
Alternative names:
-
Alternative UPACC:
P06737; A6NDQ4; B4DUB7; F5H816; O60567; O60752; O60913; Q501V9; Q641R5; Q96G82
Background:
The Glycogen phosphorylase, liver form, encoded by the gene with accession number P06737, is an allosteric enzyme pivotal in glycogen catabolism. It catalyzes the phosphorolytic cleavage of glycogen, producing glucose-1-phosphate, a critical step in maintaining glucose homeostasis at both cellular and organismal levels.
Therapeutic significance:
Glycogen storage disease 6, linked to mutations affecting this enzyme, manifests as hypoglycemia, ketosis, growth retardation, and hepatomegaly, sparing heart and skeletal muscle. Understanding the enzyme's role could unveil novel therapeutic strategies for this metabolic disorder.